Shmuel Hess Sells 3,958 Shares of MediWound (NASDAQ:MDWD) Stock

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shmuel Hess also recently made the following trade(s):

• On Wednesday, August 26th, Shmuel Hess sold 1,865 shares of MediWound stock. The shares were sold at an average price of $13.00, for a total transaction of $24,245.00.

MediWound Stock Performance

MDWD stock opened at $12.66 on Friday. MediWound Ltd. has a one year low of $12.52 and a one year high of $20.30. The firm has a market cap of $162.68 million, a price-to-earnings ratio of -7.03 and a beta of 0.15. The firm has a 50-day simple moving average of $14.16 and a two-hundred day simple moving average of $15.64.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. As a group, equities analysts predict that MediWound Ltd. will post -2.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MDWD shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Finally, Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $33.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the period. Rhumbline Advisers raised its position in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares during the period. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. Marshall Wace LLP purchased a new position in MediWound during the second quarter valued at $317,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of MediWound by 104.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 13,312 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.